1. Home
  2. FRBT vs DSGN Comparison

FRBT vs DSGN Comparison

Compare FRBT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forbright Inc. Class A Common Stock

FRBT

Forbright Inc. Class A Common Stock

N/A

Current Price

$18.58

Market Cap

948.0M

Sector

Finance

ML Signal

N/A

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

N/A

Current Price

$12.68

Market Cap

853.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRBT
DSGN
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
948.0M
853.8M
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
FRBT
DSGN
Price
$18.58
$12.68
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.25
AVG Volume (30 Days)
63.0K
666.4K
Earning Date
N/A
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.72
$5.28
52 Week High
$22.00
$17.25

Technical Indicators

Market Signals
Indicator
FRBT
DSGN
Relative Strength Index (RSI) 46.57 28.56
Support Level $18.24 $11.65
Resistance Level $19.44 $13.54
Average True Range (ATR) 0.67 0.70
MACD 0.03 -0.35
Stochastic Oscillator 47.11 3.52

Price Performance

Historical Comparison
FRBT
DSGN

About FRBT Forbright Inc. Class A Common Stock

Forbright Inc is a bank holding company. Along with its subsidiaries, it operates as a state chartered non-member bank, which serves the needs of individuals, small and medium sized businesses, and professional concerns. Its services include deposit and retail banking through a digital deposit platform, as well as financing and lending products such as lender finance loans, fund finance loans, healthcare finance loans, real estate loans, working capital facilities, warehouse lines of credit, and term loans.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: